Next Article in Journal
Sensing through Non-Sensing Ocular Ion Channels
Previous Article in Journal
Selective Elimination of NG2-Expressing Hair Follicle Stem Cells Exacerbates the Sensitization Phase of Contact Dermatitis in a Transgenic Rat Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 18
10.3390/ijms21186924
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease

by
Molly Easter
1,
Seth Bollenbecker
1,
Jarrod W. Barnes
1,2 and
Stefanie Krick
1,2,*
1
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
2
Gregory Fleming James Cystic Fibrosis Center, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(18), 6924; https://doi.org/10.3390/ijms21186924
Submission received: 5 August 2020 / Revised: 5 September 2020 / Accepted: 15 September 2020 / Published: 21 September 2020
(This article belongs to the Special Issue Therapeutic Approaches for Aging-Related Lung Disease)
Browse Figure
Review Reports Versions Notes

Abstract

:
Chronic obstructive pulmonary disease (COPD) has become a global epidemic and is the third leading cause of death worldwide. COPD is characterized by chronic airway inflammation, loss of alveolar-capillary units, and progressive decline in lung function. Major risk factors for COPD are cigarette smoking and aging. COPD-associated pathomechanisms include multiple aging pathways such as telomere attrition, epigenetic alterations, altered nutrient sensing, mitochondrial dysfunction, cell senescence, stem cell exhaustion and chronic inflammation. In this review, we will highlight the current literature that focuses on the role of age and aging-associated signaling pathways as well as their impact on current treatment strategies in the pathogenesis of COPD. Furthermore, we will discuss established and experimental COPD treatments including senolytic and anti-aging therapies and their potential use as novel treatment strategies in COPD.

1. Introduction

COPD is a progressive and debilitating respiratory condition that affects millions of people worldwide and represents a large medical and financial burden [1]. The worldwide population is living longer by 2050, 21% of the world population will be 60 years or older [2] and the prevalence of age-related chronic diseases like COPD is also increasing along with morbidity, mortality, and a greater degree of disability [3,4,5,6]. There is a five-fold increased risk for those aged over 65 years compared with patients aged less than 40 years of developing COPD [7]. In a recent report analyzing a cohort of 126,283 COPD patients (≥45 years), the prevalence of COPD was 3.6% and it increased greatly with age (1.9% in 45–64 years, 4.8% in 65–74 years, 6.8% in 75–84 years and 5.6% in ≥ 85 years) [8]. In addition, the elderly showing age-associated changes of the lung [9], which are per se not a pathological but it is unclear, whether those alterations might predispose to COPD development.
The Global Initiative of Obstructive Lung Disease (GOLD) has proposed guidelines for management and treatment of COPD; however, therapeutic interventions targeting the elderly population still need to be evaluated and translated into clinical practice [10,11]. COPD is considered a disease of accelerated aging with several aging pathways involved in its pathogenesis [12,13,14]. Current therapies mainly focus on symptomatic treatment. Thus, the understanding of age-related pathomechanisms associated with COPD is critical to uncover novel disease specific treatment strategies.

Impact and Pathophysiology of COPD in the Elderly

COPD has become the third leading cause of death worldwide with the incidence increasing with age [15]. It has been reported that COPD is 2–3 times more prevalent in the elderly, and given that the world population is aging, age will become an even more significant risk factor for COPD [16].
COPD is a chronic inflammatory disease, and it is known that increased inflammation results in a progressive decline in lung function over time [17,18]. Its pathophysiology includes irreversible airway limitation caused by long term inhalation of noxious gases and/or cigarette smoke [17,19]. Classically, COPD has been defined by two main pathologies: (1) emphysema with parenchymal destruction and loss of alveolar septa; and (2) chronic bronchitis that consists of chronic bronchial inflammation of the bronchi, which is clinically defined as a chronic cough and sputum production for 3 months for two continuous years [20]. The diagnosis is usually based on symptoms and obstructive lung function test (spirometry) values with patients often having various degrees of severity of chronic bronchitis, emphysema, or an overlap of both [11].
Particularly elderly patients with COPD suffer from additional chronic diseases such as coronary artery disease, thyroid dysfunction, hypertension, congestive heart failure, atrial fibrillation, and other cardiovascular diseases [21]. Individuals with COPD have a four-fold increase risk for cardiovascular disease, and a significantly increased risk of psychiatric, renal, neurological, gastrointestinal, and metabolic comorbidities [22,23]. These aforementioned COPD-associated comorbidities have been linked to aging-associated pathomechanisms including chronic inflammation, cell senescence and telomere shortening [23,24,25,26,27,28,29]. In addition to these mechanisms, dysregulation of the extracellular matrix including protease/anti-protease balance and dysregulated matrix metalloproteinases [30,31] also play a role in the pathogenesis of COPD in the elderly [13]. Those comorbidities and their associated pharmacological treatments make COPD therapies in the elderly even more complex and challenging.

2. Aging-Associated Molecular Mechanisms in the Pathogenesis of COPD

Aging is a progressive degeneration of tissues that has negative effects on structure and function of vital organs [32]. Age-related diseases develop when physiological anti-inflammatory and antioxidant mechanisms fail to protect the body from damage due to a persistent low-grade inflammation and increased reactive oxygen species (ROS). This imbalance leads to cell and/or tissue injury, which contributes to COPD in the elderly in combination with the general risk factors for COPD such as cigarette smoking.
Additionally, there is an age-associated decline in lung function and structural dysfunction starting in the third decade of life [33]. For example, the lung function of normal aging individuals resembles an accelerated aging profile of lung function decline (e.g., mild airflow limitation severity) in COPD consistent with early stages of the disease [12]. This loss of function in the elderly can be contributed to an underlying phenomenon that has been called the “senile lung”, which is characterized by alveolar enlargement in the absence of wall destruction [12,34,35]. In addition to lung function decline and these structural changes with age, the pulmonary defense mechanisms are less effective, leading to an increased risk of lung infections and a decreased protective response against oxidative stress and inflammation [36]. The senile lung, however, is pathophysiologically different from emphysema in COPD [9]. Several mouse models have been generated in an attempt to recapitulate the senile lung, including knockout mice deficient in klotho, the senescence marker protein-30 (SMP30), or the “Senescence-Accelerated Mouse” protein (SAM) [12,37,38,39]. In addition, Schulte and colleagues found age-related structural and functional changes in an aged mouse lung [39]. COPD animal models are a valuable tool for understanding the underlying molecular mechanisms due to the potential of genetic as well as pharmacological pathway modulation [40]. In conclusion, these mouse models demonstrate the age-associated molecular mechanisms involved in lung aging and their potential contribution to COPD independently of known mechanisms such as cigarette smoking.

2.1. Inflammaging

Aging-associated chronic low-grade inflammation (inflammaging) plays a major role in the pathogenesis of COPD and stems from an imbalance of inflammatory and anti-inflammatory networks [41]. This discrepancy increases with age, leading to increased disease susceptibility [41]. COPD-associated inflammaging is characterized by an increase in immune cells (e.g., alveolar macrophages, neutrophils, and T lymphocytes) that secrete cytokines, chemokines, growth factors and lipid mediators, which perpetuate the inflammatory process and destruction of the lung parenchyma [42]. In particular, interleukin-6 (IL-6) has been characterized as an age-related pro-inflammatory cytokine and is associated with negative health outcomes and mortality, and linked to persistent, low grade activation of chronic inflammation [43,44]. IL-6 also plays a major role in sepsis with IL-6 levels in serum correlating with onset and progression of the disease [45,46]. In addition, IL-6 was found to be increased in COPD patients with acute exacerbations [47] and was associated with the development of emphysema in COPD [48]. COPD lung cells exhibit a “senescence-associated secretory phenotype” (SASP), which is characterized by senescent lung cells secreting pro-inflammatory molecules such as IL-6, IL-8, monocyte chemoattractant protein-1, and plasminogen-activated inhibitor-1 [49,50], which further contribute to the pathogenesis of COPD.

2.2. Cell Senescence

Cell senescence is defined as an irreversible growth arrest in response to stressors such as telomere shortening, oxidative stress, stem cell depletion and persistent DNA damage [12]. Cell senescence was originally discovered in the 1960s by Hayflick when he observed that primary culture cells lost replicative capacity after several passages [51]. More recently, cellular senescence has shown to contribute to the loss of tissue homeostasis leading to the accumulation of senescent cells and contributing to the aging process [52,53,54]. Cell senescence has also been shown to contribute to the accelerated aging process in COPD [55,56]. Cigarette smoke can induce expression of the cell senescence marker p21 in epithelial cells and fibroblasts. Emphysematous lungs show increased expression of p16, p19 and p21, all of which are cyclin kinase inhibitors and markers of cell senescence [56]. Furthermore, senescent cells lose regenerative capacity and prevent cell repair in the COPD lung contributing to the progression of emphysema and worsening lung function over time.

2.3. Stem Cell Exhaustion

Stem cells play an important role in replacing cells lost to homeostatic turnover, injury, and disease [57]. With age, stem cell function and regenerative capacity decrease. Age-related decline in stem cell capacity in tissues that have regenerative potential can contribute to the development of age-associated diseases [57,58]. The lung is considered a slow renewing organ with a stable cell pool of differentiated cells and infrequent proliferation of stem cells [59]. Therefore, extensive lung injury results in limited proliferative capacity of stem cells and its consecutive depletion [60]. For example, airway basal progenitor cells play an important role in the lung’s response to injury, as they are multipotent cells that can differentiate into basal, secretory, and ciliated cells [61]. In COPD, the differentiation ability of airway basal cells is decreased, which is accompanied by an early exhaustion of airway basal progenitor cells [61,62]. Therefore, stem cell regenerative therapy could potentially benefit COPD patients, especially the elderly subpopulation.

2.4. Oxidative Stress

The free radical theory states that oxidative stress is a key driver of accelerated aging [63]. Oxidative stress arises from endogenous antioxidant defense mechanisms being overwhelmed by the presence of ROS [64]. This imbalance between pro-oxidants and anti-oxidants increases with age and leads to an accumulation of oxidative damage contributing to senescence-associated tissue injury [63]. Several studies have demonstrated that a reduction in oxidative stress leads to a longer lifespan in C. elegans, drosophila, and mice [63,65,66,67,68,69,70]. Furthermore, cigarette smoke exposure and mitochondrial dysfunction have been shown to lead to oxidative stress in COPD [71]. Oxidative stress causes DNA damage to lung cells thereby inducing additional aging hallmarks such as cellular senescence and inflammaging [72]. In summary, oxidative stress plays a role in age-associated pathomechanisms of COPD such as cellular senescence and inflammaging. Therefore, antioxidant treatments might be effective in targeting the accelerated aging process in COPD.

3. Current Treatment Options for Individuals with COPD

There is no cure for COPD; however, there are a variety of therapies that alleviate symptoms, mitigate the risk of complications, and enhance the quality and quantity of life. Current standard therapies include smoking cessation, bronchodilator therapy, oxygen supplementation, pulmonary rehabilitation, and lung transplantion [73,74,75,76,77].
Smoking cessation, when done effectively, can result in long term quit rates of up to 25% [78]. Smoking cessation is achieved through pharmacotherapies combined with counseling [77]. Pharmacotherapies consist of nicotine replacement products, including nicotine gum, nasal spray, transdermal patches, tablets, and lozenges; however, use of these products alone has a low success rate [79,80]. Counseling in combination with pharmacological products like varenicline, bupropion, and nortriptyline have been shown to be effective therapies for smoking cessation [81].
Both short- and long-acting inhaled bronchodilators, including beta adrenergic receptor agonists, and muscarinic antagonists are mainstay therapies in the pharmacological treatment regimen of COPD patients [43]. They achieve bronchodilation through the following different mechanisms: (1) muscarinic antagonists bind to M3 receptors in airway smooth muscle cells to block acetylcholine-mediated bronchoconstriction [82]; and (2) B2 agonists stimulate B2-adrenergic receptors inducing smooth muscle relaxation [83,84]. There is growing evidence that combination treatment of these long-acting bronchodilators is more beneficial than monotherapies for improving health-related quality of life, lung function, and decreasing COPD exacerbation frequency [85]. Inhaled corticosteroids (ICSs) are commonly used to treat asthma, but are also used for COPD in combination with bronchodilators, leading to a decrease in COPD exacerbations but an increased risk of pneumonia in some cases [86]. Furthermore, triple combinations are now available to treat therapy-refractory COPD patients or those with frequent exacerbations [85,87].
COPD patients with hypoxemia show an increased survival rate with supplemental oxygen therapy [88]. A more comprehensive therapy for COPD is pulmonary rehabilitation, which is a patient-tailored therapy that consists of exercise training, education and behavioral interventions. It is designed to improve the overall physical and psychological condition of COPD patients [89]. In addition, lung transplantation can be a treatment option for patients with end-stage COPD or rapidly progressing disease. Lung transplantation does not prolong survival; however, it can improve functional capacity and overall health, but advanced age is normally an exclusion criteria [90]. Double lung versus single lung transplant has been shown to provide longer survival, especially in patients older than 60 years [91]. COPD patients with severe emphysema can be treated with lung reduction surgery or endobronchial valve or coil placement to remove or reduce the emphysematous tissue, thereby decreasing hyper-inflation and providing the space of more functional lung tissue. These procedures have been shown to be beneficial for certain subgroups of COPD patients [92,93,94,95,96,97].
Together these therapies are effective in treating the symptoms of COPD, but they have not been shown to attenuate disease progression, and it is not clear whether they are as effective in the elderly population.

4. Anti-Aging Treatment Strategies in COPD

4.1. Repurposed Drugs as Potential Anti-Aging Therapies

4.1.1. Resveratrol

Resveratrol (3,4,5-trihydroxystilbene) is a plant polyphenol that is part of a family of antibiotic compounds called phytolaxins that are produced by plants in response to infections [98]. Resveratrol can be found in many common foods such as grapes, red wine, and peanuts [98]. Previous studies have shown that resveratrol can extend the life span of certain organism including yeast, drosophila, C. elegans, and fish [99,100,101]. Resveratrol has anti-inflammatory and antioxidant properties, which make it a potentially useful treatment for age-associated COPD [102,103]. Specifically, in COPD patients, resveratrol has been shown to inhibit the release of IL-8 in alveolar macrophages by 94% and 88% in smokers and patients with COPD respectively [18]. Another study showed that treatment with resveratrol reduced C-reactive protein levels and increased total antioxidant status values in smokers [102]. In a COPD rat model, resveratrol demonstrated anti-inflammatory and anti-oxidant properties by decreasing IL-6 and IL-8 production, upregulating Sirtuin1 and proliferator-activated receptor-γ coactivator-1α (PGC-1α), lowering levels of malondialdehyde and increasing superoxide dismutase activity [104]. Sirtuins are well known for their anti-aging properties [105,106,107]. Additionally, resveratrol has shown to have therapeutic effects in a COPD mouse model by decreasing the levels of the pro-inflammatory cytokines IL-17, IL-6, TNF-α, and TGF-β, attenuating fibrosis and mucus hypersecretion [108]. Together, these studies suggest that resveratrol has anti-inflammatory and anti-aging properties and could be a potential future treatment for COPD patients.

4.1.2. Metformin

Metformin is a drug widely used for the treatment of type 2 diabetes and polycystic ovary syndrome [109]. Metformin belongs to the drug class of biguanides. It suppresses endogenous glucose production mainly in the liver and increases glucose uptake in the muscle [110]. Metformin has been characterized as a ‘geroprotector’, a class of molecules that are known to have anti-aging properties [105]. Anisimov and colleagues showed that treatment with metformin increased life span by 14% and delayed tumor progression in female SHR mice [109]. Metformin activates the 5′ AMP-activated protein kinase (AMPK), which has downstream effects on the Sirtuin-forkhead box (FOXO) axis and Sirtuin-mTOR signaling. These are two important pathways for cellular response to oxidative stress which leads to attenuation of airway inflammation and lung function improvement as well as extends life span [111]. COPD is often associated with type 2 diabetes [112]. Two studies examined the effects of metformin on COPD outcomes. Hitchings and colleagues conducted a randomized control trial to examine the effects of short-term treatment with metformin on the frequency of severe COPD exacerbations in COPD patients without type 2 diabetes [113]. There was no difference in CRP and blood glucose levels after hospitalization from a severe exacerbation. This study suggests that short-term treatment with metformin is not sufficient to improve COPD symptoms. The long-term effects of metformin were not examined, which would be interesting to study since COPD is a chronic illness. A study by Bishwakarma et al. observed that patients with COPD and diabetes treated with metformin were less sick, less likely requiring oxygen, and had fewer hospitalizations when compared to patients that did not receive metformin [114].

4.1.3. Melatonin

Melatonin, N-acetyl-5-methoxytryptamine, is a hormone produced in the pineal gland that plays a key role in circadian rhythm control [115]. In addition, melatonin is a free radical scavenger for OH, O2−, and NO [116,117]. Melatonin supplementation has been shown to increase the lifespan of mice, rats, and fruit flies [117,118,119]. In patients with COPD, melatonin levels were shown to be decreased during exacerbations in combination with an increase in oxidative stress and decreases in antioxidant enzymes [120]. A randomized, double-blinded controlled trial focusing on the treatment of COPD patients with melatonin showed a decrease in oxidative stress and dyspnea after melatonin treatment and an increase in IL-8 levels in non-treated control COPD patients [121]. Additionally, melatonin treatment has been shown to reduce MUC5AC, a mucin involved in COPD-associated mucus hypersecretion [122] and IL-6 production [123]. Another report demonstrated that mice exposed to cigarette smoke and treated intraperitoneally with melatonin showed decreased total cell counts in bronchoalveolar lavage fluid (BALF), as well as decreased transforming growth factor (TGF)-β1 [124]. Together, these studies suggest that melatonin has anti-oxidative and anti-inflammatory properties and therefore might be useful in the treatment of COPD after validation in appropriate clinical trials.

4.2. The FGF23/Klotho Signaling Pathway

In 1997, Kuro-o et al. fortuitously discovered that deletion of the protein α-klotho (klotho) in a mouse model led to a premature aging phenotype including features such as skin atrophy, osteoporosis, soft tissue calcification, gonadal dysplasia, infertility, hypoglycemia, arteriosclerosis, and pulmonary emphysema [125]. Furthermore, these mice died within 8–12 weeks of age. On the other hand, overexpression of klotho in mice extended their lifespan by approximately 30% [126,127,128]. In humans, serum levels of klotho decrease with age [128] and klotho seems to play a protective role in age-related neurodegenerative disorders such as Alzheimer’s Disease [129]. Klotho is a co-receptor for fibroblast growth factor (FGF) 23, a pro-inflammatory and phosphaturic hormone, which signals through two main receptors: FGF receptor 1 (klotho dependent signaling) and FGF receptor 4 (klotho independent signaling) [130,131,132]. FGF23 is secreted by osteocytes and is important for regulating phosphate [131]. The FGF23/klotho signaling pathway has been studied in several inflammatory diseases such as heart disease, chronic kidney disease (CKD), and inflammatory airway diseases including COPD [132,133,134,135,136]. FGF23 levels have also been shown to be higher in COPD patients with more frequent exacerbations [137]. In COPD, where FGF23 levels have been shown to be elevated, klotho levels were found to be reduced. These results align with the finding that airway inflammation is modulated via the FGFR4/NFAT signaling pathway [133].
Klotho has been shown to exert anti-oxidative, anti-inflammatory, and anti-proliferative functions in the heart, lung, and kidney [135,138,139]. In the lung, klotho was shown to inhibit bronchial IL-8 secretion via attenuation of TGF-β signaling. Furthermore, klotho deficiency in the lung led to impaired mucociliary clearance [135,138]. Thus, klotho supplementation could be a useful treatment for chronic airway inflammation associated with COPD. In addition, FGFR blocking antibodies could become a novel treatment strategy to target airway inflammation. There are several FGFR inhibitors in phase 2 clinical trials for hepatocellular carcinoma [140]. Taken together, FGF23/klotho signaling may have the potential to be an amenable target pathway in the development of anti-aging and anti-inflammatory treatments in COPD.

4.3. IL-6 as an Anti-Inflammatory Therapy in COPD

Since IL-6 plays a key role in the pathogenesis of COPD, novel therapies targeting the inhibition of IL-6 would be reasonable. Previous clinical trials have used IL-6 receptor blockers in diseases such as rheumatoid arthritis and Crohn’s disease [43,141]. Furthermore, current clinical trials are investigating the use of IL-6 receptor blockers for the treatment of diseases associated with chronic inflammation such as chronic kidney disease, rheumatoid arthritis, polycystic ovarian syndrome, and Crohn’s disease. In particular, clinical trials using the IL-6 receptor blocker tocilizumab for rheumatoid arthritis were effective in decreasing circulating IL-6 levels and improving symptoms and disease activity scores [43]. To date, IL-6 receptor blockers have not been explored in COPD, but they represent a potential novel direction, requiring detailed studies to define correct timing, for an anti-aging/anti-inflammatory COPD phenotype.
A subset of COPD patients present with a predominantly IL-5 mediated eosinophilic inflammation, which has shown to contribute to exacerbation frequency and lung function decline [142,143,144]. IL-5 mediated eosinophilic inflammation plays a critical role in asthma [142,145,146] and treatments with mepolizumab [147] and reslizumab [148], which both target IL-5, are approved for asthma therapy. Age-associated differences in eosinophil activity is unclear [149,150], but for the subset of COPD patients with eosinophilic inflammation, IL-5 therapy represents a promising anti-inflammatory treatment and needs to be further explored as a potential COPD treatment strategy.

5. Potential Novel Anti-Aging Treatments for COPD

5.1. Senolytics

In recent years, senolytics have been explored as a possible treatment to “therapeutically remove” senescent cells. The ability to reduce senescent cells may result in decreased inflammation and increase the efficacy of stem and progenitor cells for tissue repair [49]. It has been shown that elimination of senescent cells might prevent or delay age-related functional impairments and extend life span [151]. Baker et al. demonstrated the ability to specifically target senescent cells in a mouse model of inducible elimination of p16-positive cells (p16Ink4a- apoptosis through targeted activation of caspase) using AP20187, which was shown to augment apoptosis [152]. Elimination of p16-positive cells has been shown to delay age-related pathologies such as sarcopenia, cataracts, and loss of adipose tissue [49,152]. Moreover, Zhu et al. discovered that senescent cells had an increased expression of pro-survival networks that confer apoptotic resistance in senescent cells [153]. Using siRNA to silence expression of key players in this pathway including ephrins (EFNB1 or 3), PI3Kd, p21, BCL-xL, and plasminogen-activated inhibitor-2, eradication of senescent cells was successfully achieved. In addition, drugs like Dasatinib and Quercetin were characterized as senolytic agents. Treatment with Dasatinib and Quercetin reduced senescent cells in aged mice and improved cardiac function and carotid vascular reactivity after single treatment [154] Recently, clinical trials examined Dasatinib and Quercetin as senolytic treatment strategies for idiopathic pulmonary fibrosis (IPF) and diabetic kidney disease [155]. Results for the IPF clinical trial showed that treatment was feasible and senolytics alleviated physical dysfunction in IPF [156]. In these studies, Dasatinib and Quercetin reduced senescent cells in the skin and SASP proteins in the blood (IL-1, IL-6, and MMP-9) [155,157]. Other senolytics such as Navitoclax, which targets BCL-2, BCL-X(l) and BCL-w, was also demonstrated to be effective in removing senescent cells, but was associated with high toxicity causing blood cell dyscrasias [155]. Moreover, cardiac glycosides such as Ouabain and Digoxin exhibit senolytic effects by inhibiting BCL-2 family proteins via inhibition of Na+/K+ ATPase [155,158]. They also exhibit selective senolytic effects on p16-expressing human airway epithelial cells [155,158]. However, to date, there are no current clinical trials assessing senolytic therapies for COPD, which may be a valid future option to investigate. Collectively, these findings demonstrate that senescent cells can be targeted and eliminated in preclinical models and patients with age-related diseases (see Table 1). Targeting senescent cells may be a potential therapy for aging-associated diseases such as COPD.

5.2. Stem Cell Therapies

In recent years, mesenchymal stem cells (MSCs) have been studied as a potential treatment for COPD [159]. MSCs are multi-potent stem cells that have fibroblast-like morphology and the capacity to differentiate into chondrocytes, osteoblasts, adipocytes, and muscle cells under different environmental conditions [160]. In addition to their regenerative properties, MSCs have distinctive anti-inflammatory properties that make them a potential treatment option for a variety of inflammatory disorders including COPD [160]. MSCs secrete anti-inflammatory molecules such as IL-10 and modulate the release of the pro-inflammatory cytokines IL-1β, TNF-α, IL-6, and prostaglandin (PG)E2 [160,161,162]. MSCs release growth factors important for tissue repair like VEGF, HGF, EGF, and TGF-β1 [160,163,164,165]. Another approach to employ stem cell therapy in COPD is through “ex vivo bioengineering” of functional lung tissue for implantation [166], which uses 3D matrices or scaffolds seeded with lung stem cells cultured to form functional lung tissue capable of gas-exchange [167]. This method has been shown to be feasible in rodents, pigs, and human lungs; however, it has yet to produce lung tissue with robust gas-exchange capacity [166,167,168]. Bioengineering of the lung has great potential as a therapy for progressive COPD due to its ability to restore damaged lung tissue and improve lung function.

5.3. Antioxidant Therapy

Antioxidant agents such as thiol molecules, especially glutathione and polyphenols, can reduce inflammatory gene expression and inhibit cigarette smoke-induced inflammatory responses [99]. Moreover, sputum from patients with stable moderate-to-severe COPD and control subjects showed increased glutathione disulfides and nitrosothiols [169]. Several clinical trials have been investigating the effects of antioxidants in different diseases (e.g., the potential of oral supplementation of glutathione in pediatric cystic fibrosis patients) and have shown a significant decrease in bowel inflammation scores following glutathione supplementation [170]. Unfortunately, lung function tests were not performed. A different clinical trial investigated inhaled glutathione as a treatment strategy for cystic fibrosis but found no clinically relevant improvements in lung function, exacerbation frequency, and patient-reported outcomes [171]. However, Lamson and colleagues published a case study using nebulized glutathione for treatment of acute respiratory crisis secondary to emphysema and found rapid resolution and improvement in respiratory function [172]. Moreover, the erdosteine thiol compound has muco-active, antioxidant and anti-inflammatory properties in addition to functioning as a modulator for bacterial adhesiveness [173]. The EQUALIFE study found that treatment with erdosteine led to a significant decrease in exacerbations and shortened hospital stay [174]. Erdosteine could prove to be an effective treatment for elderly COPD patients, especially since they are more susceptible to respiratory tract infections. In summary, more studies are needed to determine whether antioxidant therapies are useful to combat the aging process in COPD.

6. Conclusions

The lifespan of the world population is increasing, which will further enhance the prevalence of age-related diseases such as COPD. The increased lifespan and age-related diseases will ultimately put a burden on our healthcare systems and significantly affect the quality of life of these patients. Current treatments for COPD are mainly addressing COPD-associated symptoms, but alternative treatment strategies are needed to evaluate the underlying mechanisms that lead to the development of COPD, especially in the elderly (Figure 1). Therefore, it is of high interest to focus on anti-aging treatment strategies, since the numbers of the elderly with COPD will continue to rise. There are already promising therapeutic targets for aging-associated COPD pathomechanisms; however, more research needs to be conducted to better understand these mechanisms and help to develop safe and effective anti-aging therapies.

Author Contributions

M.E. and S.K. wrote the initial draft, S.B. and M.E. designed the figures and all authors edited the draft. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Flight Attendant Medical Research Institute (YFAC152003; to SK) and the Cystic Fibrosis Foundation (CFF P30 DK072482 and CFF Rowe19RO; to SK), the NIA (R03AG059994 to SK).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. May, S.M.; Li, J.T. Burden of chronic obstructive pulmonary disease: Healthcare costs and beyond. Allergy Asthma Proc. 2015, 36, 4–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Divo, M.J.; Martinez, C.H.; Mannino, D.M. Ageing and the epidemiology of multimorbidity. Eur. Respir. Soc. 2014, 44, 1055–1068. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Guilleminault, L.; Rolland, Y.; Didier, A. Characteristics of non-pharmacological interventions in the elderly with COPD. Smoking cessation, pulmonary rehabilitation, nutritional management and patient education. Rev. Mal. Respir. 2018, 35, 626–641. [Google Scholar] [CrossRef] [PubMed]
  4. Kennedy, B.K.; Berger, S.L.; Brunet, A.; Campisi, J.; Cuervo, A.M.; Epel, E.S.; Franceschi, C.; Lithgow, G.J.; Morimoto, R.I.; Pessin, J.E.; et al. Geroscience: Linking aging to chronic disease. Cell 2014, 159, 709–713. [Google Scholar] [CrossRef] [Green Version]
  5. Fragoso, C.A.V.; Gill, T.M. Defining chronic obstructive pulmonary disease in an aging population. J. Am. Geriatr. Soc. 2010, 58, 2224. [Google Scholar] [CrossRef] [Green Version]
  6. Dall, T.M.; Gallo, P.D.; Chakrabarti, R.; West, T.; Semilla, A.P.; Storm, M.V. An aging population and growing disease burden will require alarge and specialized health care workforce by 2025. Health Aff. 2013, 32, 2013–2020. [Google Scholar] [CrossRef] [Green Version]
  7. Raherison, C.; Girodet, P.-O. Epidemiology of COPD. Eur. Respir. Rev. 2009, 18, 213–221. [Google Scholar] [CrossRef]
  8. Anecchino, C.; Rossi, E.; Fanizza, C.; De Rosa, M.; Tognoni, G.; Romero, M. Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int. J. Chronic Obs. Pulm. Dis. 2007, 2, 567–574. [Google Scholar]
  9. Bellia, M.; Benfante, A.; Menozzi, M.; Augugliaro, G.; Scichilone, N.; Cannizzaro, F.; Midiri, M.; Bellia, V. Validation of lung densitometry threshold at CT for the distinction between senile lung and emphysema in elderly subjects. Monaldi Arch. Chest Dis. 2011, 75, 162–166. [Google Scholar] [CrossRef] [Green Version]
  10. Pistelli, R.; Ferrara, L.; Misuraca, C.; Bustacchini, S. Practical management problems of stable chronic obstructive pulmonary disease in the elderly. Curr. Opin. Pulm. Med. 2011, 17 (Suppl. S1), S43–S48. [Google Scholar] [CrossRef] [PubMed]
  11. Vestbo, J.; Hurd, S.S.; Agustí, A.G.; Jones, P.W.; Vogelmeier, C.; Anzueto, A.; Barnes, P.J.; Fabbri, L.M.; Martinez, F.J.; Nishimura, M.; et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013, 187, 347–365. [Google Scholar] [CrossRef] [PubMed]
  12. Meiners, S.; Eickelberg, O.; Königshoff, M. Hallmarks of the ageing lung. Eur. Respir. J. 2015, 45, 807–827. [Google Scholar] [CrossRef] [PubMed]
  13. Ito, K.; Barnes, P.J. COPD as a disease of accelerated lung aging. Chest 2009, 135, 173–180. [Google Scholar] [CrossRef]
  14. Mercado, N.; Ito, K.; Barnes, P.J. Accelerated ageing of the lung in COPD: New concepts. Thorax 2015, 70, 482–489. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Chapman, K.; Mannino, D.; Soriano, J.; Vermeire, P.; Buist, A.S.; Thun, M.; Connell, C.; Jemal, A.; Lee, T.; Miravitlles, M.; et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 2006, 27, 188–207. [Google Scholar] [CrossRef] [Green Version]
  16. Ito, K.; Mercado, N. STOP accelerating lung aging for the treatment of COPD. Exp. Gerontol. 2014, 59, 21–27. [Google Scholar] [CrossRef]
  17. Hikichi, M.; Mizumura, K.; Maruoka, S.; Gon, Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. J. Thorac. Dis. 2019, 11, S2129–S2140. [Google Scholar] [CrossRef]
  18. Culpitt, S.V.; Rogers, D.F.; Fenwick, P.S.; Shah, P.; De Matos, C.; Russell, R.E.K.; Barnes, P.J.; Donnelly, L.E. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003, 58, 942–946. [Google Scholar] [CrossRef] [Green Version]
  19. Hogg, J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004, 364, 709–721. [Google Scholar] [CrossRef]
  20. Sethi, S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000, 117, 380S–385S. [Google Scholar] [CrossRef] [Green Version]
  21. Marengoni, A.; Rizzuto, D.; Wang, H.X.; Winblad, B.; Fratiglioni, L. Patterns of chronic multimorbidity in the elderly population. J. Am. Geriatr. Soc. 2009, 57, 225–230. [Google Scholar] [CrossRef] [PubMed]
  22. Soriano, J.B.; Visick, G.T.; Muellerova, H.; Payvandi, N.; Hansell, A.L. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005, 128, 2099–2107. [Google Scholar] [CrossRef] [PubMed]
  23. Pedone, C. Comorbidities of COPD as a function of age: Evidence and practical recommendations. J. Gerontol. Geriatr. 2016, 64, 126–130. [Google Scholar]
  24. De Miguel Díez, J.; Morgan, J.C.; García, R.J. The association between COPD and heart failure risk: A review. Int. J. Chronic Obstr. Pulm. Dis. 2013, 8, 305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Incalzi, R.A.; Corsonello, A.; Pedone, C.; Battaglia, S.; Paglino, G.; Bellia, V. Extrapulmonary Consequences of COPD in the Elderly Study Investigators. S. Chronic renal failure: A neglected comorbidity of COPD. Chest 2010, 137, 831–837. [Google Scholar] [PubMed]
  26. Maurer, J.; Rebbapragada, V.; Borson, S.; Goldstein, R.; Kunik, M.E.; Yohannes, A.M.; Hanania, N.A. Anxiety and depression in COPD: Current understanding, unanswered questions, and research needs. Chest 2008, 134, 43S–56S. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Graat-Verboom, L.; Wouters, E.; Smeenk, F.; Van Den Borne, B.; Lunde, R.; Spruit, M. Current status of research on osteoporosis in COPD: A systematic review. Eur. Respir. J. 2009, 34, 209–218. [Google Scholar] [CrossRef] [Green Version]
  28. Barnes, P.J. Senescence in COPD and Its Comorbidities. Annu. Rev. Physiol. 2017, 79, 517–539. [Google Scholar] [CrossRef]
  29. Córdoba-Lanús, E.; Cazorla-Rivero, S.; Espinoza-Jiménez, A.; de-Torres, J.P.; Pajares, M.J.; Aguirre-Jaime, A.; Celli, B.; Casanova, C. Telomere shortening and accelerated aging in COPD: Findings from the BODE cohort. Respir. Res. 2017, 18, 59. [Google Scholar] [CrossRef] [Green Version]
  30. Churg, A.; Zhou, S.; Wright, J.L. Series “matrix metalloproteinases in lung health and disease”: Matrix metalloproteinases in COPD. Eur. Respir. J. 2012, 39, 197–209. [Google Scholar] [CrossRef]
  31. Shapiro, S.D.; Ingenito, E.P. The pathogenesis of chronic obstructive pulmonary disease: Advances in the past 100 years. Am. J. Respir. Cell Mol. Biol. 2005, 32, 367–372. [Google Scholar] [CrossRef] [PubMed]
  32. MacNee, W. Is Chronic Obstructive Pulmonary Disease an Accelerated Aging Disease? Ann. Am. Thorac. Soc. 2016, 13 (Suppl. S5), S429–S437. [Google Scholar] [CrossRef] [PubMed]
  33. Fragoso, C.A.V. Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) in Aging Populations. COPD J. Chronic Obstr. Pulm. Dis. 2016, 13, 125–129. [Google Scholar] [CrossRef] [PubMed]
  34. Teramoto, S.; Ishii, M. Aging, the aging lung, and senile emphysema are different. Am. J. Respir. Crit. Care Med. 2007, 175, 197–198. [Google Scholar] [CrossRef] [PubMed]
  35. Janssens, J.-P.; Pache, J.-C.; Nicod, L. Physiological changes in respiratory function associated with ageing. Eur. Respir. J. 1999, 13, 197–205. [Google Scholar] [CrossRef] [PubMed]
  36. Brandsma, C.-A.; de Vries, M.; Costa, R.; Woldhuis, R.R.; Königshoff, M.; Timens, W. Lung ageing and COPD: Is there a role for ageing in abnormal tissue repair? Eur. Respir. Rev. 2017, 26, 170073. [Google Scholar] [CrossRef] [Green Version]
  37. Sato, A.; Hirai, T.; Imura, A.; Kita, N.; Iwano, A.; Muro, S.; Nabeshima, Y.; Suki, B.; Mishima, M. Morphological mechanism of the development of pulmonary emphysema in klotho mice. Proc. Natl. Acad. Sci. USA 2007, 104, 2361–2365. [Google Scholar] [CrossRef] [Green Version]
  38. Teramoto, S.; Fukuchi, Y.; Uejima, Y.; Teramoto, K.; Oka, T.; Orimo, H. A novel model of senile lung: Senescence-accelerated mouse (SAM). Am. J. Respir. Crit. Care Med. 1994, 150, 238–244. [Google Scholar] [CrossRef]
  39. Schulte, H.; Mühlfeld, C.; Brandenberger, C. Age-Related Structural and Functional Changes in the Mouse Lung. Front. Physiol. 2019, 10, 1466. [Google Scholar] [CrossRef] [Green Version]
  40. Vandivier, R.W.; Ghosh, M. Understanding the Relevance of the Mouse Cigarette Smoke Model of COPD: Peering through the Smoke. Am. J. Respir. Cell. Mol. Biol. 2017, 57, 3–4. [Google Scholar] [CrossRef] [Green Version]
  41. Franceschi, C.; Garagnani, P.; Vitale, G.; Capri, M.; Salvioli, S. Inflammaging and ‘Garb-aging’. Trends Endocrinol. Metab. 2017, 28, 199–212. [Google Scholar] [CrossRef] [PubMed]
  42. Barnes, P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2016, 138, 16–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Garth, J.; Barnes, J.W.; Krick, S. Targeting cytokines as evolving treatment strategies in chronic inflammatory airway diseases. Int. J. Mol. Sci. 2018, 19, 3402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Franceschi, C.; Capri, M.; Monti, D.; Giunta, S.; Olivieri, F.; Sevini, F.; Panourgia, M.P.; Invidia, L.; Celani, L.; Scurti, M.; et al. Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 2007, 128, 92–105. [Google Scholar] [CrossRef]
  45. Remick, D.G.; Bolgos, G.; Copeland, S.; Siddiqui, J. Role of Interleukin-6 in Mortality from and Physiologic Response to Sepsis. Infect. Immun. 2005, 73, 2751–2757. [Google Scholar] [CrossRef] [Green Version]
  46. Damas, P.; Ledoux, D.; Nys, M.; Vrindts, Y.; De Groote, D.; Franchimont, P.; Lamy, M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann. Surg. 1992, 215, 356. [Google Scholar] [CrossRef]
  47. Wedzicha, J.A.; Seemungal, T.A.; MacCallum, P.K.; Paul, E.A.; Donaldson, G.C.; Bhowmik, A.; Jeffries, D.J.; Meade, T.W. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb. Haemost. 2000, 84, 210–215. [Google Scholar]
  48. Song, W.; Zhao, J.; Li, Z. Interleukin-6 in bronchoalveolar lavage fluid from patients with COPD. Chin. Med. J. 2001, 114, 1140–1142. [Google Scholar]
  49. Kirkland, J.L.; Tchkonia, T.; Zhu, Y.; Niedernhofer, L.J.; Robbins, P.D. The Clinical Potential of Senolytic Drugs. J. Am. Geriatr. Soc. 2017, 65, 2297–2301. [Google Scholar] [CrossRef]
  50. Freund, A.; Orjalo, A.V.; Desprez, P.Y.; Campisi, J. Inflammatory networks during cellular senescence: Causes and consequences. Trends Mol. Med. 2010, 16, 238–246. [Google Scholar] [CrossRef] [Green Version]
  51. Hayflick, L.; Moorhead, P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25, 585–621. [Google Scholar] [CrossRef]
  52. Wang, C.; Jurk, D.; Maddick, M.; Nelson, G.; Martin-Ruiz, C.; Von Zglinicki, T. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell 2009, 8, 311–323. [Google Scholar] [CrossRef] [PubMed]
  53. Herbig, U.; Ferreira, M.; Condel, L.; Carey, D.; Sedivy, J.M. Cellular senescence in aging primates. Science 2006, 311, 1257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Passos, J.F.; Nelson, G.; Wang, C.; Richter, T.; Simillion, C.; Proctor, C.J.; Miwa, S.; Olijslagers, S.; Hallinan, J.; Wipat, A. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol. Syst. Biol. 2010, 6, 347. [Google Scholar] [CrossRef] [PubMed]
  55. Chilosi, M.; Carloni, A.; Rossi, A.; Poletti, V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl. Res. 2013, 162, 156–173. [Google Scholar] [CrossRef]
  56. Tuder, R.M.; Kern, J.A.; Miller, Y.E. Senescence in Chronic Obstructive Pulmonary Disease. Proc. Am. Thorac. Soc. 2012, 9, 62–63. [Google Scholar] [CrossRef]
  57. Signer, R.A.; Morrison, S.J. Mechanisms that regulate stem cell aging and life span. Cell Stem Cell 2013, 12, 152–165. [Google Scholar] [CrossRef] [Green Version]
  58. Ruzankina, Y.; Asare, A.; Brown, E.J. Replicative stress, stem cells and aging. Mech. Ageing Dev. 2008, 129, 460–466. [Google Scholar] [CrossRef] [Green Version]
  59. Stripp, B.R.; Reynolds, S.D. Maintenance and repair of the bronchiolar epithelium. Proc. Am. Thorac. Soc. 2008, 5, 328–333. [Google Scholar] [CrossRef]
  60. Ghosh, M.; Miller, Y.E.; Nakachi, I.; Kwon, J.B.; Barón, A.E.; Brantley, A.E.; Merrick, D.T.; Franklin, W.A.; Keith, R.L.; Vandivier, R.W. Exhaustion of airway basal progenitor cells in early and established chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2018, 197, 885–896. [Google Scholar] [CrossRef]
  61. Staudt, M.R.; Buro-Auriemma, L.J.; Walters, M.S.; Salit, J.; Vincent, T.; Shaykhiev, R.; Mezey, J.G.; Tilley, A.E.; Kaner, R.J.; Ho, M.W.; et al. Airway Basal stem/progenitor cells have diminished capacity to regenerate airway epithelium in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2014, 190, 955–958. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Zhang, Y.; Unnikrishnan, A.; Deepa, S.S.; Liu, Y.; Li, Y.; Ikeno, Y.; Sosnowska, D.; Van Remmen, H.; Richardson, A. A new role for oxidative stress in aging: The accelerated aging phenotype in Sod1−/− mice is correlated to increased cellular senescence. Redox Biol. 2017, 11, 30–37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Kirkham, P.A.; Barnes, P.J. Oxidative stress in COPD. Chest 2013, 144, 266–273. [Google Scholar] [CrossRef]
  64. Pérez, V.I.; Bokov, A.; Van Remmen, H.; Mele, J.; Ran, Q.; Ikeno, Y.; Richardson, A. Is the oxidative stress theory of aging dead? Biochim. Biophys. Acta 2009, 1790, 1005–1014. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Lithgow, G.J.; White, T.M.; Melov, S.; Johnson, T.E. Thermotolerance and extended life-span conferred by single-gene mutations and induced by thermal stress. Proc. Natl. Acad. Sci. USA 1995, 92, 7540–7544. [Google Scholar] [CrossRef] [Green Version]
  66. Johnson, T.E.; Lithgow, G.J.; Murakami, S. Hypothesis: Interventions that increase the response to stress offer the potential for effective life prolongation and increased health. J. Gerontol. Ser. A Biol. Sci. Med Sci. 1996, 51, B392–B395. [Google Scholar] [CrossRef] [Green Version]
  67. Murakami, S.; Salmon, A.; Miller, R.A. Multiplex stress resistance in cells from long-lived dwarf mice. FASEB J. 2003, 17, 1565–1576. [Google Scholar] [CrossRef]
  68. Migliaccio, E.; Giorgio, M.; Mele, S.; Pelicci, G.; Reboldi, P.; Pandolfi, P.P.; Lanfrancone, L.; Pelicci, P.G. The p66 shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999, 402, 309–313. [Google Scholar] [CrossRef]
  69. Holzenberger, M.; Dupont, J.; Ducos, B.; Leneuve, P.; Géloën, A.; Even, P.C.; Cervera, P.; Le Bouc, Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003, 421, 182–187. [Google Scholar] [CrossRef]
  70. Boukhenouna, S.; Wilson, M.A.; Bahmed, K.; Kosmider, B. Reactive Oxygen Species in Chronic Obstructive Pulmonary Disease. Oxid. Med. Cell Longev. 2018, 2018, 5730395. [Google Scholar] [CrossRef]
  71. Aoshiba, K.; Tsuji, T.; Yamaguchi, K.; Itoh, M.; Nakamura, H. The danger signal plus DNA damage two-hit hypothesis for chronic inflammation in COPD. Eur. Respir. J. 2013, 42, 1689–1695. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Hanania, N.A.; Ambrosino, N.; Calverley, P.; Cazzola, M.; Donner, C.F.; Make, B. Treatments for COPD. Respir. Med. 2005, 99, S28–S40. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Mulhall, P.; Criner, G. Non-pharmacological treatments for COPD. Respirology 2016, 21, 791–809. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Thabut, G.; Dauriat, G.; Stern, J.B.; Logeart, D.; Levy, A.; Marrash-Chahla, R.; Mal, H. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005, 127, 1531–1536. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Stoller, J.K.; Panos, R.J.; Krachman, S.; Doherty, D.E.; Make, B.; Group, Long-term Oxygen Treatment Trial Research Group. Oxygen therapy for patients with COPD: Current evidence and the long-term oxygen treatment trial. Chest 2010, 138, 179–187. [Google Scholar] [CrossRef] [Green Version]
  76. Willemse, B.W.; ten Hacken, N.H.; Rutgers, B.; Lesman-Leegte, I.G.; Postma, D.S.; Timens, W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur. Respir. J. 2005, 26, 835–845. [Google Scholar] [CrossRef]
  77. van Eerd, E.A.; van der Meer, R.M.; van Schayck, O.C.; Kotz, D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2016, 2016, Cd010744. [Google Scholar] [CrossRef]
  78. Frishman, W.H.; Mitta, W.; Kupersmith, A.; Ky, T. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol. Rev. 2006, 14, 57–73. [Google Scholar] [CrossRef]
  79. CADTH. CADTH Rapid Response Reports. In Nicotine Replacement Therapy for Smoking Cessation or Reduction: A Review of the Clinical Evidence; Canadian Agency for Drugs and Technologies in Health: Ottawa, ON, Canada, 2014. [Google Scholar]
  80. Aubin, H.J.; Luquiens, A.; Berlin, I. Pharmacotherapy for smoking cessation: Pharmacological principles and clinical practice. Br. J. Clin. Pharmacol. 2014, 77, 324–336. [Google Scholar] [CrossRef]
  81. Buels, K.S.; Fryer, A.D. Muscarinic receptor antagonists: Effects on pulmonary function. In Handbook of Experimental Pharmacology; Spinger: Berlin/Heidelberg, Germany, 2012; pp. 317–341. [Google Scholar]
  82. Lipson, D.A.; Barnacle, H.; Birk, R.; Brealey, N.; Locantore, N.; Lomas, D.A.; Ludwig-Sengpiel, A.; Mohindra, R.; Tabberer, M.; Zhu, C.-Q.; et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2017, 196, 438–446. [Google Scholar] [CrossRef] [Green Version]
  83. Rossi, A.; Khirani, S.; Cazzola, M. Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: Efficacy and safety. Int. J. Chronic Obstr. Pulm. Dis. 2008, 3, 521. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Singh, D. New combination bronchodilators for chronic obstructive pulmonary disease: Current evidence and future perspectives. Br. J. Clin. Pharmacol. 2015, 79, 695–708. [Google Scholar] [CrossRef] [Green Version]
  85. Agusti, A.; Fabbri, L.M.; Singh, D.; Vestbo, J.; Celli, B.; Franssen, F.M.; Rabe, K.F.; Papi, A. Inhaled corticosteroids in COPD: Friend or foe? Eur. Respir. J. 2018, 52, 1801219. [Google Scholar] [CrossRef] [PubMed]
  86. Lipson, D.A.; Barnhart, F.; Brealey, N.; Brooks, J.; Criner, G.J.; Day, N.C.; Dransfield, M.T.; Halpin, D.M.G.; Han, M.K.; Jones, C.E.; et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N. Engl. J. Med. 2018, 378, 1671–1680. [Google Scholar] [CrossRef]
  87. McDonald, C.F. Oxygen therapy for COPD. J. Thorac. Dis. 2014, 6, 1632–1639. [Google Scholar] [PubMed]
  88. Reardon, J.; Casaburi, R.; Morgan, M.; Nici, L.; Rochester, C. Pulmonary rehabilitation for COPD. Respir. Med. 2005, 99, S19–S27. [Google Scholar] [CrossRef] [Green Version]
  89. Patel, N.; DeCamp, M.; Criner, G.J. Lung transplantation and lung volume reduction surgery versus transplantation in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2008, 5, 447–453. [Google Scholar] [CrossRef]
  90. Subramanian, M.P.; Meyers, B.F. Bilateral versus single lung transplantation: Are two lungs better than one? J. Thorac. Dis. 2018, 10, 4588–4601. [Google Scholar] [CrossRef] [Green Version]
  91. National Emphysema Treatment Trial Research Group. A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe Emphysema. N. Engl. J. Med. 2003, 348, 2059–2073. [Google Scholar] [CrossRef]
  92. Refaely, Y.; Dransfield, M.; Kramer, M.; Gotfried, M.; Leeds, W.; McLennan, G.; Tewari, S.; Krasna, M.; Criner, G. Biologic lung volume reduction therapy for advanced homogeneous emphysema. Eur. Respir. J. 2010, 36, 20–27. [Google Scholar] [CrossRef] [Green Version]
  93. Fishman, A.; Fessler, H.; Martinez, F.; McKenna, R.J., Jr.; Naunheim, K.; Piantadosi, S.; Weinmann, G.; Wise, R. Patients at high risk of death after lung-volume-reduction surgery. N. Engl. J. Med. 2001, 345, 1075–1083. [Google Scholar]
  94. Criner, G.J.; Delage, A.; Voelker, K.; Hogarth, D.K.; Majid, A.; Zgoda, M.; Lazarus, D.R.; Casal, R.; Benzaquen, S.B.; Holladay, R.C.; et al. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. Am. J. Respir. Crit. Care Med. 2019, 200, 1354–1362. [Google Scholar] [CrossRef] [PubMed]
  95. Sciurba, F.C.; Criner, G.J.; Strange, C.; Shah, P.L.; Michaud, G.; Connolly, T.A.; Deslée, G.; Tillis, W.P.; Delage, A.; Marquette, C.H.; et al. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. JAMA 2016, 315, 2178–2189. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Dransfield, M.T.; Garner, J.L.; Bhatt, S.P.; Slebos, D.J.; Klooster, K.; Sciurba, F.C.; Shah, P.L.; Marchetti, N.T.; Sue, R.D.; Wright, S.; et al. Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. Ann. Am. Thorac. Soc. 2020, 17, 829–838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Knutson, M.D.; Leeuwenburgh, C. Resveratrol and novel potent activators of Sirt1: Effects on aging and age-related diseases. Nutr. Rev. 2008, 66, 591–596. [Google Scholar] [CrossRef] [PubMed]
  98. Rahman, I. Antioxidant therapies in COPD. Int. J. Chronic Obs. Pulm. Dis. 2006, 1, 15–29. [Google Scholar] [CrossRef]
  99. Zou, S.; Carey, J.R.; Liedo, P.; Ingram, D.K.; Müller, H.G.; Wang, J.L.; Yao, F.; Yu, B.; Zhou, A. The prolongevity effect of resveratrol depends on dietary composition and calorie intake in a tephritid fruit fly. Exp. Gerontol. 2009, 44, 472–476. [Google Scholar] [CrossRef] [Green Version]
  100. Tatar, M. Diet restriction in Drosophila melanogaster. Design and analysis. Interdiscip. Top. Gerontol. 2007, 35, 115–136. [Google Scholar]
  101. Bo, S.; Ciccone, G.; Castiglione, A.; Gambino, R.; De Michieli, F.; Villois, P.; Durazzo, M.; Cavallo-Perin, P.; Cassader, M. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr. Med. Chem. 2013, 20, 1323–1331. [Google Scholar] [CrossRef]
  102. Beijers, R.; Gosker, H.R.; Schols, A. Resveratrol for patients with chronic obstructive pulmonary disease: Hype or hope? Curr. Opin. Clin. Nutr. Metab. Care 2018, 21, 138–144. [Google Scholar] [CrossRef]
  103. Wang, X.-L.; Li, T.; Li, J.-H.; Miao, S.-Y.; Xiao, X.-Z. The effects of resveratrol on inflammation and oxidative stress in a rat model of chronic obstructive pulmonary disease. Molecules 2017, 22, 1529. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Ito, K.; Colley, T.; Mercado, N. Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease. Int. J. Chronic Obstr. Pulm. Dis. 2012, 7, 641. [Google Scholar] [CrossRef] [Green Version]
  105. Ghosh, H.S. The anti-aging, metabolism potential of SIRT1. Curr. Opin. Investig. Drugs 2008, 9, 1095–1102. [Google Scholar] [PubMed]
  106. Grabowska, W.; Sikora, E.; Bielak-Zmijewska, A. Sirtuins, a promising target in slowing down the ageing process. Biogerontology 2017, 18, 447–476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  107. Chen, J.; Yang, X.; Zhang, W.; Peng, D.; Xia, Y.; Lu, Y.; Han, X.; Song, G.; Zhu, J.; Liu, R. Therapeutic effects of resveratrol in a mouse model of LPS and cigarette smoke-induced COPD. Inflammation 2016, 39, 1949–1959. [Google Scholar] [CrossRef] [PubMed]
  108. Anisimov, V.N.; Berstein, L.M.; Popovich, I.G.; Zabezhinski, M.A.; Egormin, P.A.; Piskunova, T.S.; Semenchenko, A.V.; Tyndyk, M.L.; Yurova, M.N.; Kovalenko, I.G.; et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging 2011, 3, 148–157. [Google Scholar] [CrossRef] [Green Version]
  109. Rena, G.; Hardie, D.G.; Pearson, E.R. The mechanisms of action of metformin. Diabetologia 2017, 60, 1577–1585. [Google Scholar] [CrossRef] [Green Version]
  110. Piskovatska, V.; Stefanyshyn, N.; Storey, K.B.; Vaiserman, A.M.; Lushchak, O. Metformin as a geroprotector: Experimental and clinical evidence. Biogerontology 2019, 20, 33–48. [Google Scholar] [CrossRef]
  111. Ho, T.W.; Huang, C.T.; Ruan, S.Y.; Tsai, Y.J.; Lai, F.; Yu, C.J. Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality. PLoS ONE 2017, 12, e0175794. [Google Scholar] [CrossRef]
  112. Hitchings, A.W.; Lai, D.; Jones, P.W.; Baker, E.H. Metformin in severe exacerbations of chronic obstructive pulmonary disease: A randomised controlled trial. Thorax 2016, 71, 587–593. [Google Scholar] [CrossRef] [Green Version]
  113. Bishwakarma, R.; Zhang, W.; Lin, Y.-L.; Kuo, Y.-F.; Cardenas, V.J.; Sharma, G. Metformin use and health care utilization in patients with coexisting chronic obstructive pulmonary disease and diabetes mellitus. Int. J. Chronic Obstr. Pulm. Dis. 2018, 13, 793. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Reiter, R.J.; Tan, D.-X.; Poeggeler, B.; Menendez-Pelaez, A.; Chen, L.-D.; Saarela, S. Melatonin As a Free Radical Scavenger: Implications for Aging and Age-Related Diseasesa. Ann. N. Y. Acad. Sci. 1994, 719, 1–12. [Google Scholar] [CrossRef] [PubMed]
  115. Poeggeler, B.; Thuermann, S.; Dose, A.; Schoenke, M.; Burkhardt, S.; Hardeland, R. Melatonin’s unique radical scavenging properties—Roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal Res. 2002, 33, 20–30. [Google Scholar] [CrossRef] [PubMed]
  116. Anisimov, V.N.; Popovich, I.G.; Zabezhinski, M.A.; Anisimov, S.V.; Vesnushkin, G.M.; Vinogradova, I.A. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim. Biophys. Acta 2006, 1757, 573–589. [Google Scholar] [CrossRef] [Green Version]
  117. Anisimov, V.N.; Alimova, I.N.; Baturin, D.A.; Popovich, I.G.; Zabezhinski, M.A.; Rosenfeld, S.V.; Manton, K.G.; Semenchenko, A.V.; Yashin, A.I. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice. Exp. Gerontol. 2003, 38, 449–461. [Google Scholar] [CrossRef]
  118. Bonilla, E.; Medina-Leendertz, S.; Díaz, S. Extension of life span and stress resistance of Drosophila melanogaster by long-term supplementation with melatonin. Exp. Gerontol. 2002, 37, 629–638. [Google Scholar] [CrossRef]
  119. Gumral, N.; Nazıroglu, M.; Ongel, K.; Beydilli, E.D.; Ozguner, F.; Sutcu, R.; Calıskan, S.; Akkaya, A. Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. Cell Biochem. Funct. 2009, 27, 276–283. [Google Scholar] [CrossRef]
  120. de Matos Cavalcante, A.G.; de Bruin, P.F.C.; de Bruin, V.M.S.; Nunes, D.M.; Pereira, E.D.B.; Cavalcante, M.M.; Andrade, G.M. Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled study. J. Pineal Res. 2012, 53, 238–244. [Google Scholar] [CrossRef]
  121. Kesimer, M.; Ford, A.A.; Ceppe, A.; Radicioni, G.; Cao, R.; Davis, C.W.; Doerschuk, C.M.; Alexis, N.E.; Anderson, W.H.; Henderson, A.G.; et al. Airway Mucin Concentration as a Marker of Chronic Bronchitis. N. Engl. J. Med. 2017, 377, 911–922. [Google Scholar] [CrossRef]
  122. Shin, I.-S.; Park, J.-W.; Shin, N.-R.; Jeon, C.-M.; Kwon, O.-K.; Lee, M.-Y.; Kim, H.-S.; Kim, J.-C.; Oh, S.-R.; Ahn, K.-S. Melatonin inhibits MUC5AC production via suppression of MAPK signaling in human airway epithelial cells. J. Pineal Res. 2014, 56, 398–407. [Google Scholar] [CrossRef]
  123. Shin, N.-R.; Park, J.-W.; Lee, I.-C.; Ko, J.-W.; Park, S.-H.; Kim, J.-S.; Kim, J.-C.; Ahn, K.-S.; Shin, I.-S. Melatonin suppresses fibrotic responses induced by cigarette smoke via downregulation of TGF-β1. Oncotarget 2017, 8, 95692–95703. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  124. Kuro-o, M.; Matsumura, Y.; Aizawa, H.; Kawaguchi, H.; Suga, T.; Utsugi, T.; Ohyama, Y.; Kurabayashi, M.; Kaname, T.; Kume, E.; et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390, 45–51. [Google Scholar] [CrossRef] [PubMed]
  125. Kurosu, H.; Yamamoto, M.; Clark, J.D.; Pastor, J.V.; Nandi, A.; Gurnani, P.; McGuinness, O.P.; Chikuda, H.; Yamaguchi, M.; Kawaguchi, H.; et al. Suppression of aging in mice by the hormone Klotho. Science 2005, 309, 1829–1833. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  126. Chen, T.H.; Kuro, O.M.; Chen, C.H.; Sue, Y.M.; Chen, Y.C.; Wu, H.H.; Cheng, C.Y. The secreted Klotho protein restores phosphate retention and suppresses accelerated aging in Klotho mutant mice. Eur. J. Pharmacol. 2013, 698, 67–73. [Google Scholar] [CrossRef] [PubMed]
  127. Xu, Y.; Sun, Z. Molecular basis of Klotho: From gene to function in aging. Endocr. Rev. 2015, 36, 174–193. [Google Scholar] [CrossRef] [Green Version]
  128. Torbus-Paluszczak, M.; Bartman, W.; Adamczyk-Sowa, M. Klotho protein in neurodegenerative disorders. Neurol. Sci. 2018, 39, 1677–1682. [Google Scholar] [CrossRef] [Green Version]
  129. Erben, R.G. Update on FGF23 and Klotho signaling. Mol. Cell Endocrinol. 2016, 432, 56–65. [Google Scholar] [CrossRef]
  130. Grabner, A.; Amaral, A.P.; Schramm, K.; Singh, S.; Sloan, A.; Yanucil, C.; Li, J.; Shehadeh, L.A.; Hare, J.M.; David, V.; et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015, 22, 1020–1032. [Google Scholar] [CrossRef] [Green Version]
  131. Lu, X.; Hu, M.C. Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease. Kidney Dis. 2017, 3, 15–23. [Google Scholar] [CrossRef] [Green Version]
  132. Krick, S.; Grabner, A.; Baumlin, N.; Yanucil, C.; Helton, S.; Grosche, A.; Sailland, J.; Geraghty, P.; Viera, L.; Russell, D.W.; et al. Fibroblast growth factor 23 and Klotho contribute to airway inflammation. Eur. Respir. J. 2018, 52, 1800236. [Google Scholar] [CrossRef] [Green Version]
  133. Singh, S.; Grabner, A.; Yanucil, C.; Schramm, K.; Czaya, B.; Krick, S.; Czaja, M.J.; Bartz, R.; Abraham, R.; Di Marco, G.S.; et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016, 90, 985–996. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  134. Krick, S.; Baumlin, N.; Aller, S.P.; Aguiar, C.; Grabner, A.; Sailland, J.; Mendes, E.; Schmid, A.; Qi, L.; David, N.V.; et al. Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia. Sci. Rep. 2017, 7, 14388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  135. Barnes, J.W.; Duncan, D.; Helton, S.; Hutcheson, S.; Kurundkar, D.; Logsdon, N.J.; Locy, M.; Garth, J.; Denson, R.; Farver, C.; et al. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2019, 317, L141–L154. [Google Scholar] [CrossRef] [PubMed]
  136. Gulati, S.; Wells, J.M.; Urdaneta, G.P.; Balestrini, K.; Vital, I.; Tovar, K.; Barnes, J.W.; Bhatt, S.P.; Campos, M.; Krick, S. Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study. Int. J. Mol. Sci. 2019, 20, 2292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  137. Garth, J.; Easter, M.; Skylar Harris, E.; Sailland, J.; Kuenzi, L.; Chung, S.; Dennis, J.S.; Baumlin, N.; Adewale, A.T.; Rowe, S.M.; et al. The Effects of the Anti-aging Protein Klotho on Mucociliary Clearance. Front. Med. (Lausanne) 2019, 6, 339. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  138. Doi, S.; Zou, Y.; Togao, O.; Pastor, J.V.; John, G.B.; Wang, L.; Shiizaki, K.; Gotschall, R.; Schiavi, S.; Yorioka, N.; et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J. Biol. Chem. 2011, 286, 8655–8665. [Google Scholar] [CrossRef] [Green Version]
  139. Raja, A.; Park, I.; Haq, F.; Ahn, S.-M. FGF19-FGFR4 Signaling in Hepatocellular Carcinoma. Cells 2019, 8, 536. [Google Scholar] [CrossRef] [Green Version]
  140. Choy, E.; Isenberg, D.; Garrood, T.; Farrow, S.; Ioannou, Y.; Bird, H.; Cheung, N.; Williams, B.; Hazleman, B.; Price, R.; et al. Therapeutic benefit of blocking interleukin-6 activity with an anti–interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002, 46, 3143–3150. [Google Scholar] [CrossRef]
  141. Saha, S.; Brightling, C.E. Eosinophilic airway inflammation in COPD. Int. J. Chronic Obs. Pulm. Dis. 2006, 1, 39–47. [Google Scholar] [CrossRef] [Green Version]
  142. Narendra, D.K.; Hanania, N.A. Targeting IL-5 in COPD. Int. J. Chronic Obs. Pulm. Dis. 2019, 14, 1045–1051. [Google Scholar] [CrossRef] [Green Version]
  143. Singh, D.; Kolsum, U.; Brightling, C.E.; Locantore, N.; Agusti, A.; Tal-Singer, R. Eosinophilic inflammation in COPD: Prevalence and clinical characteristics. Eur. Respir. J. 2014, 44, 1697–1700. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  144. Zeiger, R.S.; Schatz, M.; Li, Q.; Chen, W.; Khatry, D.B.; Gossage, D.; Tran, T.N. High Blood Eosinophil Count Is a Risk Factor for Future Asthma Exacerbations in Adult Persistent Asthma. J. Allergy Clin. Immunol. Pract. 2014, 2, 741–750. [Google Scholar] [CrossRef] [PubMed]
  145. Tran, T.N.; Khatry, D.B.; Ke, X.; Ward, C.K.; Gossage, D. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann. Allergy Asthma Immunol. 2014, 113, 19–24. [Google Scholar] [CrossRef] [PubMed]
  146. Fala, L. Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma. Am. Health Drug Benefits 2016, 9, 106–110. [Google Scholar]
  147. Hom, S.; Pisano, M. Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype. Pharm. Ther. 2017, 42, 564–568. [Google Scholar]
  148. Mathur, S.K.; Schwantes, E.A.; Jarjour, N.N.; Busse, W.W. Age-related changes in eosinophil function in human subjects. Chest 2008, 133, 412–419. [Google Scholar] [CrossRef] [Green Version]
  149. Busse, P.J.; Zhang, T.F.; Srivastava, K.; Schofield, B.; Li, X.M. Effect of ageing on pulmonary inflammation, airway hyperresponsiveness and T and B cell responses in antigen-sensitized and -challenged mice. Clin. Exp. Allergy 2007, 37, 1392–1403. [Google Scholar] [CrossRef] [PubMed]
  150. Cazzola, M.; Matera, M.G.; Rogliani, P.; Calzetta, L. Senolytic drugs in respiratory medicine: Is it an appropriate therapeutic approach? Expert Opin. Investig. Drugs 2018, 27, 573–581. [Google Scholar] [CrossRef]
  151. Baker, D.J.; Wijshake, T.; Tchkonia, T.; LeBrasseur, N.K.; Childs, B.G.; van de Sluis, B.; Kirkland, J.L.; van Deursen, J.M. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011, 479, 232–236. [Google Scholar] [CrossRef] [PubMed]
  152. Zhu, Y.; Tchkonia, T.; Pirtskhalava, T.; Gower, A.C.; Ding, H.; Giorgadze, N.; Palmer, A.K.; Ikeno, Y.; Hubbard, G.B.; Lenburg, M.; et al. The Achilles’ heel of senescent cells: From transcriptome to senolytic drugs. Aging Cell 2015, 14, 644–658. [Google Scholar] [CrossRef] [PubMed]
  153. Baker, J.R.; Donnelly, L.E.; Barnes, P.J. Senotherapy: A New Horizon for COPD Therapy. Chest 2020, 158, 562–570. [Google Scholar] [CrossRef]
  154. Roos, C.M.; Zhang, B.; Palmer, A.K.; Ogrodnik, M.B.; Pirtskhalava, T.; Thalji, N.M.; Hagler, M.; Jurk, D.; Smith, L.A.; Casaclang-Verzosa, G.; et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 2016, 15, 973–977. [Google Scholar] [CrossRef] [PubMed]
  155. Justice, J.N.; Nambiar, A.M.; Tchkonia, T.; LeBrasseur, N.K.; Pascual, R.; Hashmi, S.K.; Prata, L.; Masternak, M.M.; Kritchevsky, S.B.; Musi, N.; et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine 2019, 40, 554–563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  156. Hickson, L.J.; Prata, L.G.L.; Bobart, S.A.; Evans, T.K.; Giorgadze, N.; Hashmi, S.K.; Herrmann, S.M.; Jensen, M.D.; Jia, Q.; Jordan, K.L.; et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 2019, 47, 446–456. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  157. Guerrero, A.; Herranz, N.; Sun, B.; Wagner, V.; Gallage, S.; Guiho, R.; Wolter, K.; Pombo, J.; Irvine, E.E.; Innes, A.J.; et al. Cardiac glycosides are broad-spectrum senolytics. Nat. Metab. 2019, 1, 1074–1088. [Google Scholar] [CrossRef]
  158. Broekman, W.; Khedoe, P.P.; Schepers, K.; Roelofs, H.; Stolk, J.; Hiemstra, P.S. Mesenchymal stromal cells: A novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax 2018, 73, 565–574. [Google Scholar] [CrossRef] [Green Version]
  159. Liu, X.; Fang, Q.; Kim, H. Preclinical studies of mesenchymal stem cell (MSC) administration in chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis. PLoS ONE 2016, 11, e0157099. [Google Scholar] [CrossRef]
  160. Zhang, W.-G.; He, L.; Shi, X.-M.; Wu, S.-S.; Zhang, B.; Mei, L.; Xu, Y.-J.; Zhang, Z.-X.; Zhao, J.-P.; Zhang, H.-L. Regulation of transplanted mesenchymal stem cells by the lung progenitor niche in rats with chronic obstructive pulmonary disease. Respir. Res. 2014, 15, 33. [Google Scholar] [CrossRef] [Green Version]
  161. Gu, W.; Song, L.; Li, X.-M.; Wang, D.; Guo, X.-J.; Xu, W.-G. Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways. Sci. Rep. 2015, 5, 8733. [Google Scholar] [CrossRef] [Green Version]
  162. Zhen, G.; Xue, Z.; Zhao, J.; Gu, N.; Tang, Z.; Xu, Y.; Zhang, Z. Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. Cytotherapy 2010, 12, 605–614. [Google Scholar] [CrossRef]
  163. Kim, Y.-S.; Kim, J.-Y.; Huh, J.W.; Lee, S.W.; Choi, S.J.; Oh, Y.-M. The therapeutic effects of optimal dose of mesenchymal stem cells in a murine model of an elastase induced-emphysema. Tuberc. Respir. Dis. 2015, 78, 239–245. [Google Scholar] [CrossRef] [PubMed]
  164. Guan, X.J.; Song, L.; Han, F.F.; Cui, Z.L.; Chen, X.; Guo, X.J.; Xu, W.G. Mesenchymal stem cells protect cigarette smoke-damaged lung and pulmonary function partly via VEGF–VEGF receptors. J. Cell. Biochem. 2013, 114, 323–335. [Google Scholar] [CrossRef] [PubMed]
  165. Weiss, D.J. Cell-based Therapy for Chronic Obstructive Pulmonary Disease. Rebuilding the Lung. Ann. Am. Thorac. Soc. 2018, 15 (Suppl. S4), S253–S259. [Google Scholar] [CrossRef] [PubMed]
  166. Wagner, D.E.; Bonvillain, R.W.; Jensen, T.; Girard, E.D.; Bunnell, B.A.; Finck, C.M.; Hoffman, A.M.; Weiss, D.J. Can stem cells be used to generate new lungs? Ex vivo lung bioengineering with decellularized whole lung scaffolds. Respirology 2013, 18, 895–911. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  167. Horváth, L.; Umehara, Y.; Jud, C.; Blank, F.; Petri-Fink, A.; Rothen-Rutishauser, B. Engineering an in vitro air-blood barrier by 3D bioprinting. Sci. Rep. 2015, 5, 7974. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  168. Beeh, K.M.; Beier, J.; Koppenhoefer, N.; Buhl, R. Increased glutathione disulfide and nitrosothiols in sputum supernatant of patients with stable COPD. Chest 2004, 126, 1116–1122. [Google Scholar] [CrossRef]
  169. Ciofu, O.; Smith, S.; Lykkesfeldt, J. Antioxidant supplementation for lung disease in cystic fibrosis. Cochrane Database Syst. Rev. 2019, 10, Cd007020. [Google Scholar] [CrossRef]
  170. Griese, M.; Kappler, M.; Eismann, C.; Ballmann, M.; Junge, S.; Rietschel, E.; van Koningsbruggen-Rietschel, S.; Staab, D.; Rolinck-Werninghaus, C.; Mellies, U.; et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am. J. Respir. Crit. Care Med. 2013, 188, 83–89. [Google Scholar] [CrossRef]
  171. Lamson, D.W.; Brignall, M.S. The use of nebulized glutathione in the treatment of emphysema: A case report. Altern. Med. Rev. 2000, 5, 429–431. [Google Scholar]
  172. Dal Negro, R.W.; Wedzicha, J.A.; Iversen, M.; Fontana, G.; Page, C.; Cicero, A.F.; Pozzi, E.; Calverley, P.M. Effect of erdosteine on the rate and duration of COPD exacerbations: The RESTORE study. Eur. Respir. J. 2017, 50, 1700711. [Google Scholar] [CrossRef] [Green Version]
  173. Moretti, M.; Bottrighi, P.; Dallari, R.; Da Porto, R.; Dolcetti, A.; Grandi, P.; Garuti, G.; Guffanti, E.; Roversi, P.; De Gugliemo, M.; et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: The EQUALIFE Study. Drugs Exp. Clin. Res. 2004, 30, 143–152. [Google Scholar] [PubMed]
  174. Meyer, K.C. Lung infections and aging. Ageing Res. Rev. 2004, 3, 55–67. [Google Scholar] [CrossRef] [PubMed]
Ijms 21 06924 g001 550
Figure 1. Diagram depicting two major risk factors for COPD cigarette smoke and aging. These risk factors cause downstream pathologies such as inflammaging, cell senescence, stem cell exhaustion and oxidative stress, which can be targeted with the treatment options shown in the orange and white box: anti-inflammatory therapy, senolytics, stem cell therapy and antioxidant therapy.
Figure 1. Diagram depicting two major risk factors for COPD cigarette smoke and aging. These risk factors cause downstream pathologies such as inflammaging, cell senescence, stem cell exhaustion and oxidative stress, which can be targeted with the treatment options shown in the orange and white box: anti-inflammatory therapy, senolytics, stem cell therapy and antioxidant therapy.
Ijms 21 06924 g001
Table
Table 1. A table of senolytic drugs. This table includes the molecular targets of each of the drugs and the progress to becoming a therapy for senescence.
Table 1. A table of senolytic drugs. This table includes the molecular targets of each of the drugs and the progress to becoming a therapy for senescence.
SenolyticsTargetModel
DasatinibTyrosine KinasesPhase 2 Clincal Trial
QuercetinTyrosine KinasesPhase 2 Clincal Trial
NavitovlaxBCL–2 FamilyAnimal Models
Cardiag GlycosidesBCL–2 FamilyAnimal Models

Share and Cite

MDPI and ACS Style

Easter, M.; Bollenbecker, S.; Barnes, J.W.; Krick, S. Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease. Int. J. Mol. Sci. 2020, 21, 6924. https://doi.org/10.3390/ijms21186924

AMA Style

Easter M, Bollenbecker S, Barnes JW, Krick S. Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences. 2020; 21(18):6924. https://doi.org/10.3390/ijms21186924

Chicago/Turabian Style

Easter, Molly, Seth Bollenbecker, Jarrod W. Barnes, and Stefanie Krick. 2020. "Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease" International Journal of Molecular Sciences 21, no. 18: 6924. https://doi.org/10.3390/ijms21186924

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop